[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100301154":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":38,"collaborators":7,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":7,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Kaohsiung Medical University Chung-Ho Memorial Hospital","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"directly acting antivirals (DAAs)","Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.",[13],{"name":14,"affiliation":15,"role":16},"Ming-Lung Yu, MD., PhD","HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":21,"email":22},"CONTACT","88673121101","7475","fish6069@gmail.com",[24],{"facility":15,"status":25,"city":26,"state":7,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","Kaohsiung City","807","Taiwan",{"type":30,"coordinates":31},"Point",[32,33],120.31333,22.61626,{"lat":33,"lon":32},[36,37],{"name":14,"role":19,"phone":20,"phoneExt":21,"email":22},{"name":14,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100301154",false,"NCT03200379","Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan","Inclusion Criteria:\n\n1\\. Patients who are treated with DAA and have willingness to participate in this registry.\n\nExclusion Criteria:\n\nChronic hepatitis C patients who are unwilling to participate in the study and do not provide written informed consent for participation.","ALL",{"count":47,"type":48},150000,"ESTIMATED","OBSERVATIONAL","To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan",[52],"Hepatitis C, Chronic","2022-04-06",{"date":55,"type":56},"2022-04-08","ACTUAL",{"date":58,"type":56},"2017-06-15",{"date":60,"type":48},"2037-06-15",{"name":5,"class":6},1]